Michelle A. Rudek, Pharm.D., Ph.D is an Associate Professor of Oncology and Medicine (Clinical Pharmacology) at the Johns Hopkins University School of Medicine. She received her Pharm.D., Ph.D. from Virginia Commonwealth University in a joint program with the National Cancer Institute (NCI). Dr. Rudek’s expertise is associated with studying the pharmacokinetic-pharmacodynamic properties of anticancer agents with a focus on special populations (AIDS malignancy and organ dysfunction). Dr. Rudek is the Subject Matter Expert in Pharmacology of the NCI’s Investigational Drug Steering Committee (IDSC), Chair of the NCI’s IDSC Pharmacology Task Force, Co-chair of the NCI’s Organ Dysfunction Working Group (ODWG), Co-chair of the AIDS Malignancy Clinical (AMC) Trials Consortium Translational Science Working Group, member of the Adult Brain Tumor Consortium (ABTC) Pharmacology Committee, and member of the NCI’s Adult Central Institutional Review Board (CIRB)-Early Phase Emphasis. She has authored over 120 scientific papers in peer reviewed journals focused on the clinical pharmacology of anti-cancer drug. Dr. Rudek is an active member of the American Society of Clinical Pharmacology and Therapeutics and serves on the editorial board of several journals.
